

# Daniel A Arber

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3430088/publications.pdf>

Version: 2024-02-01

72  
papers

14,508  
citations

257101

24  
h-index

114278

63  
g-index

72  
all docs

72  
docs citations

72  
times ranked

14577  
citing authors

#	ARTICLE	IF	CITATIONS
1	The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. <i>Blood</i> , 2016, 127, 2391-2405.	0.6	7,429
2	The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. <i>Blood</i> , 2009, 114, 937-951.	0.6	3,864
3	International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. <i>Blood</i> , 2022, 140, 1200-1228.	0.6	814
4	Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E1116-25.	3.3	307
5	Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future. <i>Cancer Research</i> , 2017, 77, 1261-1270.	0.4	210
6	Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms. <i>Blood</i> , 2014, 123, 2645-2651.	0.6	192
7	Clinical characterization of acute myeloid leukemia with myelodysplasia-related changes as defined by the 2008 WHO classification system. <i>Blood</i> , 2009, 113, 1906-1908.	0.6	149
8	Bone Marrow Biopsy Involvement by Non-Hodgkin's Lymphoma. <i>American Journal of Surgical Pathology</i> , 2005, 29, 1549-1557.	2.1	119
9	Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutations. <i>Modern Pathology</i> , 2015, 28, 706-714.	2.9	114
10	Targeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specified. <i>Modern Pathology</i> , 2016, 29, 854-864.	2.9	104
11	Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions. <i>Haematologica</i> , 2019, 104, 1935-1949.	1.7	93
12	Initial Diagnostic Workup of Acute Leukemia: Guideline From the College of American Pathologists and the American Society of Hematology. <i>Archives of Pathology and Laboratory Medicine</i> , 2017, 141, 1342-1393.	1.2	88
13	<i>t</i> (11q23) TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML. <i>Blood Advances</i> , 2022, 6, 2847-2853.	2.5	87
14	Mixed Phenotype Acute Leukemia. <i>American Journal of Clinical Pathology</i> , 2014, 142, 803-808.	0.4	62
15	Bone marrow morphology is a strong discriminator between chronic eosinophilic leukemia, not otherwise specified and reactive idiopathic hypereosinophilic syndrome. <i>Haematologica</i> , 2017, 102, 1352-1360.	1.7	62
16	Oligomonocytic chronic myelomonocytic leukemia (chronic myelomonocytic leukemia without) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 14 chronic myelomonocytic leukemia. <i>Modern Pathology</i> , 2017, 30, 1213-1222.	2.9	52
17	Hematopoietic neoplasms with 9p24/JAK2 rearrangement: a multicenter study. <i>Modern Pathology</i> , 2019, 32, 490-498.	2.9	50
18	The 2016 WHO classification of acute myeloid leukemia: What the practicing clinician needs to know. <i>Seminars in Hematology</i> , 2019, 56, 90-95.	1.8	48

#	ARTICLE	IF	CITATIONS
19	A study of the mutational landscape of pediatric-type follicular lymphoma and pediatric nodal marginal zone lymphoma. <i>Modern Pathology</i> , 2016, 29, 1212-1220.	2.9	46
20	Immunohistochemistry for p53 is a useful tool to identify cases of acute myeloid leukemia with myelodysplasia-related changes that are TP53 mutated, have complex karyotype, and have poor prognosis. <i>Modern Pathology</i> , 2017, 30, 382-392.	2.9	43
21	STAT3 mutations are present in aggressive B-cell lymphomas including a subset of diffuse large B-cell lymphomas with CD30 expression. <i>Haematologica</i> , 2014, 99, e105-e105.	1.7	37
22	Myeloproliferative neoplasms with concurrent BCR-ABL1 translocation and JAK2 V617F mutation: a multi-institutional study from the bone marrow pathology group. <i>Modern Pathology</i> , 2018, 31, 690-704.	2.9	35
23	Reclassifying myelodysplastic syndromes: what's where in the new WHO and why. <i>Hematology American Society of Hematology Education Program</i> , 2015, 2015, 294-298.	0.9	34
24	Classification of myeloid neoplasms/acute leukemia: Global perspectives and the international consensus classification approach. <i>American Journal of Hematology</i> , 2022, 97, 514-518.	2.0	30
25	Comparison of therapy-related and de novo core binding factor acute myeloid leukemia: A bone marrow pathology group study. <i>American Journal of Hematology</i> , 2020, 95, 799-808.	2.0	26
26	Clinical, immunophenotypic, and genomic findings of acute undifferentiated leukemia and comparison to acute myeloid leukemia with minimal differentiation: a study from the bone marrow pathology group. <i>Modern Pathology</i> , 2019, 32, 1373-1385.	2.9	25
27	Diagnosis and Treatment of Patients With Acute Myeloid Leukemia With Myelodysplasia-Related Changes (AML-MRC). <i>American Journal of Clinical Pathology</i> , 2020, 154, 731-741.	0.4	22
28	Prognostic Significance of Complex Karyotypes in Acute Myeloid Leukemia. <i>Current Treatment Options in Oncology</i> , 2019, 20, 15.	1.3	21
29	Concordance among hematopathologists in classifying blasts plus promonocytes: A bone marrow pathology group study. <i>International Journal of Laboratory Hematology</i> , 2020, 42, 418-422.	0.7	21
30	Myeloid/lymphoid neoplasms with FLT3 rearrangement. <i>Modern Pathology</i> , 2021, 34, 1673-1685.	2.9	21
31	Acute Myeloid Leukemia With Monosomal Karyotype. <i>American Journal of Clinical Pathology</i> , 2014, 142, 190-195.	0.4	20
32	Frequency of MAP2K1, TP53, and U2AF1 Mutations in BRAF-mutated Langerhans Cell Histiocytosis. <i>American Journal of Surgical Pathology</i> , 2018, 42, 885-890.	2.1	19
33	Two cases of histiocytic sarcoma with BCL2 translocations and occult or subsequent follicular lymphoma. <i>Human Pathology</i> , 2016, 55, 39-43.	1.1	18
34	Myelodysplastic Syndrome, Unclassifiable (MDS-U) With 1% Blasts Is a Distinct Subgroup of MDS-U With a Poor Prognosis. <i>American Journal of Clinical Pathology</i> , 2017, 148, 49-57.	0.4	18
35	Update on the pathologic diagnosis of chronic myelomonocytic leukemia. <i>Modern Pathology</i> , 2019, 32, 732-740.	2.9	18
36	Acute Myeloid Leukemia With Myelodysplasia-Related Changes: A New Definition. <i>Surgical Pathology Clinics</i> , 2010, 3, 1153-1164.	0.7	15

#	ARTICLE	IF	CITATIONS
37	A Survey of Somatic Mutations in 41 Genes in a Cohort of T-Cell Lymphomas Identifies Frequent Mutations in Genes Involved in Epigenetic Modification. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2019, 27, 416-422.	0.6	15
38	Revisiting erythroleukemia. <i>Current Opinion in Hematology</i> , 2017, 24, 146-151.	1.2	15
39	Lymphoid blast transformation in an MPN with <i>BCR-JAK2</i> treated with ruxolitinib: putative mechanisms of resistance. <i>Blood Advances</i> , 2021, 5, 3492-3496.	2.5	14
40	Genetic Testing in the Diagnosis and Biology of Acute Leukemia. <i>American Journal of Clinical Pathology</i> , 2019, 152, 322-346.	0.4	13
41	Significance of myelodysplastic syndrome-associated somatic variants in the evaluation of patients with pancytopenia and idiopathic cytopenias of undetermined significance. <i>Modern Pathology</i> , 2016, 29, 996-1003.	2.9	12
42	Diagnosis and treatment of mixed phenotype (T-myeloid/lymphoid) acute leukemia with novel <i>ETV6-FGFR2</i> rearrangement. <i>Blood Advances</i> , 2020, 4, 4924-4928.	2.5	12
43	Evaluation of Testing of Acute Leukemia Samples: Survey Result From the College of American Pathologists. <i>Archives of Pathology and Laboratory Medicine</i> , 2017, 141, 1101-1106.	1.2	11
44	High-throughput Sequencing of Subcutaneous Panniculitis-like T-Cell Lymphoma Reveals Candidate Pathogenic Mutations. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2019, 27, 740-748.	0.6	11
45	How I investigate chronic myelomonocytic leukemia. <i>International Journal of Laboratory Hematology</i> , 2020, 42, 101-108.	0.7	9
46	Chronic myeloid neoplasms harboring concomitant mutations in myeloproliferative neoplasm driver genes ( <i>JAK2/MPL/CALR</i> ) and <i>SF3B1</i> . <i>Modern Pathology</i> , 2021, 34, 20-31.	2.9	9
47	The utility of IgM, CD21, HGAL and LMO2 in the diagnosis of pediatric follicular lymphoma. <i>Human Pathology</i> , 2015, 46, 629-633.	1.1	8
48	Clinical, immunophenotypic and genomic findings of NK lymphoblastic leukemia: a study from the Bone Marrow Pathology Group. <i>Modern Pathology</i> , 2021, 34, 1358-1366.	2.9	8
49	Challenges in Consolidated Reporting of Hematopoietic Neoplasms. <i>Surgical Pathology Clinics</i> , 2013, 6, 795-806.	0.7	7
50	Diagnosis of classic Hodgkin lymphoma on bone marrow biopsy. <i>Histopathology</i> , 2020, 76, 934-941.	1.6	7
51	Vascular neoplasms and non-neoplastic vascular lesions of the spleen. <i>Seminars in Diagnostic Pathology</i> , 2021, 38, 154-158.	1.0	6
52	Erythroleukemia: an Update. <i>Current Oncology Reports</i> , 2021, 23, 69.	1.8	6
53	Primary Gastric Hodgkin's Lymphoma: An Extremely Rare Entity and A Diagnostic Challenge. <i>Digestive Diseases and Sciences</i> , 2015, 60, 2923-2926.	1.1	5
54	The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia. , 2020, 8, e000810.		5

#	ARTICLE	IF	CITATIONS
55	Aggressive B-cell lymphomas with a primary bone marrow presentation. <i>Histopathology</i> , 2020, 77, 369-379.	1.6	4
56	How I Diagnose Acute Leukemia of Ambiguous Lineage. <i>American Journal of Clinical Pathology</i> , 2022, 158, 27-34.	0.4	4
57	A reevaluation of erythroid predominance in Acute Myeloid Leukemia using the updated WHO 2016 Criteria. <i>Modern Pathology</i> , 2018, 31, 873-880.	2.9	3
58	Non-hematopoietic neoplastic and pseudoneoplastic lesions of the spleen. <i>Seminars in Diagnostic Pathology</i> , 2021, 38, 159-164.	1.0	3
59	<i>NPM1</i> exon 5 mutations in acute myeloid leukemia: Implications in diagnosis and minimal residual monitoring. <i>EJHaem</i> , 2022, 3, 962-965.	0.4	2
60	EAHP 2020 workshop proceedings, pediatric myeloid neoplasms. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, 481, 621-646.	1.4	2
61	Challenges and limitations in the primary diagnosis of T-cell and natural killer cell/T-cell lymphoma in bone marrow biopsy. <i>Histopathology</i> , 2020, 77, 2-17.	1.6	1
62	Pathology of the spleen: INTRODUCTION. <i>Seminars in Diagnostic Pathology</i> , 2021, 38, 111.	1.0	1
63	AML Patients with Monosomal Karyotype Are Characterized by Absence of <i>NPM1</i> and <i>FLT3</i> Mutations and Worse Clinical Outcome.. <i>Blood</i> , 2009, 114, 2638-2638.	0.6	1
64	<i>GLUT1</i> Immunohistochemistry Is a Highly Sensitive and Relatively Specific Marker for Erythroid Lineage in Benign and Malignant Hematopoietic Tissues. <i>American Journal of Clinical Pathology</i> , 2022, 158, 228-234.	0.4	1
65	Why Is Hematopathology so Complicated?. <i>Surgical Pathology Clinics</i> , 2013, 6, ix.	0.7	0
66	Biological characterization of stage I follicular lymphoma according to extranodal or nodal primary origin and t(14;18) status using high-resolution array-based comparative genomic hybridization. <i>American Journal of Hematology</i> , 2015, 90, E151-2.	2.0	0
67	Clinical Characterization of Acute Myeloid Leukemia with Myelodysplasia-Related Changes as Defined by the 2008 WHO Classification System.. <i>Blood</i> , 2008, 112, 922-922.	0.6	0
68	2008 WHO Classification of Pediatric AML.. <i>Blood</i> , 2010, 116, 1044-1044.	0.6	0
69	Temozolomide In Acute Myeloid Leukemia: A <i>MGMT</i> Promoter Methylation Status-Based Treatment Stratification. <i>Blood</i> , 2010, 116, 3313-3313.	0.6	0
70	Immature T-Cell Populations in Lymph Nodes of Castleman Disease and Angioimmunoblastic T-Cell Lymphoma Suggest Alternate Sites of T-Cell Development,. <i>Blood</i> , 2011, 118, 3238-3238.	0.6	0
71	Clinicopathologic Characterization of Acute Myeloid Leukemia and Myelodysplastic Syndrome with Inv(3)(q21;q26.2)/t(3;3)(q21;q26.2) Reveals That Complex Karyotype but Not Blast Percentage Is Associated with Poor Survival; A Bone Marrow Pathology Group Study. <i>Blood</i> , 2012, 120, 3847-3847.	0.6	0
72	Myelodysplastic/Myeloproliferative Neoplasms. , 2020, , 162-180.		0